Last reviewed · How we verify

BBI608 — Competitive Intelligence Brief

BBI608 (BBI608) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Wnt/β-catenin pathway inhibitor. Area: Oncology.

phase 3 Wnt/β-catenin pathway inhibitor β-catenin / Wnt signaling pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BBI608 (BBI608) — NCIC Clinical Trials Group. BBI608 is a Wnt/β-catenin pathway inhibitor that targets cancer stem cells by blocking their self-renewal capacity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BBI608 TARGET BBI608 NCIC Clinical Trials Group phase 3 Wnt/β-catenin pathway inhibitor β-catenin / Wnt signaling pathway
EM-100 EM-100 Bausch & Lomb Incorporated phase 3 Wnt/β-catenin pathway inhibitor Wnt/β-catenin signaling pathway
ISV-403 ISV-403 Bausch & Lomb Incorporated phase 3 Wnt/β-catenin pathway inhibitor Wnt/β-catenin signaling pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Wnt/β-catenin pathway inhibitor class)

  1. Bausch & Lomb Incorporated · 2 drugs in this class
  2. NCIC Clinical Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BBI608 — Competitive Intelligence Brief. https://druglandscape.com/ci/bbi608. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: